Developer docs
API playgroundTry for free, no card

Search company profiles

Cantourage

Full company profile

uuid000b4vu

Namestring
Cantourage
Legal namestring
Cantourage GmbH
Websiteurl
cantourage.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Cantourage is a Berlin-based European medical cannabis company founded in 2019 and listed on the Frankfurt Stock Exchange (ticker HIGH) since November 2022. The company operates an asset-light platform that imports dried cannabis flowers from a network of 60+ cultivation partners across 18 countries, processes them to EU-GMP pharmaceutical standards at facilities in Germany and Portugal, and distributes the finished pharmaceutical-grade products to pharmacies across 8 European markets (Germany, UK, Austria, Switzerland, Poland, Czech Republic, Denmark). Cantourage also produces and distributes cannabis extracts, dronabinol (pure THC), and CBD products.

Its core technology is the Fast Track Access platform, a proprietary system that consolidates the complex, multi-step process of bringing international cannabis raw materials into European pharmaceutical compliance — handling import, trimming, microbiological reduction, packaging, labelling, testing, market release, warehousing, and fulfilment. This is paired with telemedicine front-ends: Telecan in Germany and Cantourage Clinic in the UK, which enable patients to obtain cannabis prescriptions online and have them fulfilled via partner pharmacies.

Cantourage's revenue model is a transaction-fee / revenue-share arrangement: the company does not own cultivation assets but earns on the processing and distribution margin when third-party cultivators' products are sold into European pharmacies. GTM is hybrid — sales-led B2B to pharmacies and physicians across its eight markets, complemented by direct-to-patient prescription generation through its telehealth platforms. The company achieved break-even in 2023 on the strength of this asset-light structure, with revenue subsequently accelerating to EUR 92.8M (preliminary) in FY2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis distribution, pharmaceutical cannabis processing, cannabis telemedicine services, dronabinol CBD extracts, EU-GMP cannabis manufacturing
Industry3 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Medical Cannabis Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cannabis flower processing and distribution
TypeTransaction Fee
Description

Cantourage imports cannabis flowers from its global network of 60+ cultivators in 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal, and distributes pharmaceutical-grade dried cannabis flowers to pharmacies across Europe. Revenue is generated through the sale of processed cannabis flowers under a revenue-sharing model with cultivators.

cantourage.com
2Extracts, Dronabinol and CBD
TypeTransaction Fee
Description

Cantourage produces and distributes extracts, dronabinol (pure THC), and Cannabidiol (CBD) products across all relevant pharmaceutical market segments. These are sold to pharmacies and healthcare providers.

cantourage.com
3Exclusive distribution partnerships
TypeTransaction Fee
Description

Cantourage holds exclusive distribution rights for certain product lines including Portocanna's Hexacan brand and specific strains from cultivation partners, expanding its portfolio without additional cultivation investment.

cantourage.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Telecan
Description

Telemedicine platform for cannabis prescriptions in Germany, enabling patients to consult with doctors and receive prescriptions online

cantourage.com
+3 more records
Core offering1 text field

Cantourage imports cannabis raw materials from over 60 cultivation partners across 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal into pharmaceutical-grade products (dried flowers, extracts, dronabinol, and CBD), and distributes them to pharmacies across eight European markets under a revenue-sharing model with cultivators. The company complements its product business with patient-facing telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that enable online cannabis prescriptions from experienced cannabis physicians.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue of EUR 92.8 million in 2025, up from EUR 51.4 million in 2024 (118% year-over-year growth)
+3 more records
Product overview1 text field

Cantourage is a European medical cannabis platform that operates a portfolio of products and services. Their core offering includes the Fast Track Access Platform enabling international cultivators to access European markets, combined with pharmaceutical-grade products across all market segments: dried cannabis flowers (imported from 60+ cultivators across 18 countries), cannabis extracts, Dronabinol (pure THC), and CBD products. The company complements its product business with telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that facilitate patient access to cannabis prescriptions. Distribution reaches pharmacies in Germany, the UK, Austria, Switzerland, Poland, Czech Republic, and Denmark.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-04
Description

Polish pharmaceutical distributor partnership for Cantourage's cannabis products. PharmaVitae distributes Cantourage's Gelato 33 and MAC 1 strains to pharmacies across Poland. The partnership targets at least doubling sales from around 500 kg in 2025 to over 1 tonne of cannabis flowers in 2026. PharmaVitae is a Polish private company founded in 2011, specializing in import and distribution of Rx and OTC medicines, medical devices, and cosmetics. It generated PLN 80 million in revenue in 2023.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-04
Description

Canadian cannabis cultivator supplying the Gelato 33 strain to Cantourage for distribution in Poland through the PharmaVitae partnership. LOT420 is a Canadian producer committed to providing patients with the best possible quality cannabis products.

3Portocanna
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

Exclusive strategic partnership with Portuguese medical cannabis processor Portocanna. Portocanna's state-of-the-art EU-GMP certified production facility serves as an additional processing site for Cantourage's cannabis flowers from 65+ cultivation partners in 18 countries, increasing Cantourage's processing capacity by up to six tons per year. The first two products (Supreme Diesel and Fiji Sunset from Green Karat) processed at Portocanna are available in German pharmacies. Additionally, Cantourage gained exclusive distribution rights for Portocanna's 'Hexacan' product line.

cantourage.com
4Green Karat
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Cultivation partner supplying cannabis strains (Supreme Diesel and Fiji Sunset) to Cantourage. Products processed at Portocanna and distributed in German pharmacies.

cantourage.com
5Cantourage UK
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UK subsidiary of Cantourage that distributes products to pharmacies in the United Kingdom and operates the Cantourage Clinic telehealth platform for UK patients.

cantourage.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Canadian-listed multinational cannabis company with EU medical cannabis distribution. Comparable at the cross-border medical cannabis wholesale layer, though significantly larger and broader than Cantourage's platform.

TypeDirect peer
Description

Frankfurt-based medical cannabis operator focused on EU-GMP-certified cultivation and pharmacy distribution across Germany and other European markets. Comparable as a regulated EU medical cannabis producer/distributor competing for the same pharmacy channel.

TypeBroad incumbent
Description

German-headquartered European pharmaceutical generics and specialty company with a growing cannabis portfolio (e.g., through partnerships). Comparable as a regulated pharma distribution channel that competes for medical cannabis shelf space in German pharmacies.

TypeBroad incumbent
Description

Canadian-listed global cannabis producer with European medical cannabis operations. Comparable as a multi-country medical cannabis wholesale supplier but with an integrated cultivation footprint that Cantourage deliberately avoids.

TypeDirect peer
Description

Berlin-based medical cannabis company operating in Germany across cultivation, processing, and distribution. Directly comparable to Cantourage as a fellow German-headquartered medical cannabis platform with vertically integrated pharmacy and patient access.

TypeDirect peer
Description

German medical cannabis importer and wholesaler supplying pharmacies across Germany. Directly comparable to Cantourage's wholesale pharmacy distribution model, including its multi-supplier flower portfolio strategy.

TypeDirect peer
Description

German medical cannabis producer and distributor serving German pharmacies. Directly comparable as a domestic competitor in EU-GMP-certified flower and extract supply to the same pharmacy channels Cantourage targets.

TypeDirect peer
Description

German medical cannabis producer and distributor selling pharmaceutical-grade cannabis to pharmacies. Comparable as a domestic competitor in flower and extract supply to the same regulated German pharmacy channel.

TypeDirect peer
Description

German medical cannabis distributor and telemedicine operator. Closely comparable to Cantourage because it combines pharmacy-channel distribution with its own doctor/patient access platform — the same hybrid model Cantourage runs via Telecan.

10Tilray Brands
TypeBroad incumbent
Description

Large global cannabis incumbent with established EU medical cannabis operations. Comparable to Cantourage at the wholesale/pharmacy-distribution layer but operates a much broader product and geographic portfolio at scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cantourage

Medical Cannabis Pharmaceuticalscantourage.com

What Cantourage does

Cantourage is a Berlin-based European medical cannabis company founded in 2019 and listed on the Frankfurt Stock Exchange (ticker HIGH) since November 2022. The company operates an asset-light platform that imports dried cannabis flowers from a network of 60+ cultivation partners across 18 countries, processes them to EU-GMP pharmaceutical standards at facilities in Germany and Portugal, and distributes the finished pharmaceutical-grade products to pharmacies across 8 European markets (Germany, UK, Austria, Switzerland, Poland, Czech Republic, Denmark). Cantourage also produces and distributes cannabis extracts, dronabinol (pure THC), and CBD products.

Its core technology is the Fast Track Access platform, a proprietary system that consolidates the complex, multi-step process of bringing international cannabis raw materials into European pharmaceutical compliance — handling import, trimming, microbiological reduction, packaging, labelling, testing, market release, warehousing, and fulfilment. This is paired with telemedicine front-ends: Telecan in Germany and Cantourage Clinic in the UK, which enable patients to obtain cannabis prescriptions online and have them fulfilled via partner pharmacies.

Cantourage's revenue model is a transaction-fee / revenue-share arrangement: the company does not own cultivation assets but earns on the processing and distribution margin when third-party cultivators' products are sold into European pharmacies. GTM is hybrid — sales-led B2B to pharmacies and physicians across its eight markets, complemented by direct-to-patient prescription generation through its telehealth platforms. The company achieved break-even in 2023 on the strength of this asset-light structure, with revenue subsequently accelerating to EUR 92.8M (preliminary) in FY2025.

Cantourage firmographics

Firmographics
Name
Cantourage
Legal name
Cantourage GmbH
Website
https://cantourage.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Cantourage industry classification

Industry
Product category
Medical Cannabis Pharmaceuticals
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Medicinal and Botanical Manufacturing (325411)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medical cannabis distribution
  • Pharmaceutical cannabis processing
  • Cannabis telemedicine services
  • Dronabinol CBD extracts
  • EU-GMP cannabis manufacturing

Where Cantourage is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Cantourage business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Cannabis flower processing and distribution: Cantourage imports cannabis flowers from its global network of 60+ cultivators in 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal, and distributes pharmaceutical-grade dried cannabis flowers to pharmacies across Europe. Revenue is generated through the sale of processed cannabis flowers under a revenue-sharing model with cultivators.
  2. Extracts, Dronabinol and CBD: Cantourage produces and distributes extracts, dronabinol (pure THC), and Cannabidiol (CBD) products across all relevant pharmaceutical market segments. These are sold to pharmacies and healthcare providers.
  3. Exclusive distribution partnerships: Cantourage holds exclusive distribution rights for certain product lines including Portocanna's Hexacan brand and specific strains from cultivation partners, expanding its portfolio without additional cultivation investment.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Cantourage product offering

Product offering

Core offering

Cantourage imports cannabis raw materials from over 60 cultivation partners across 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal into pharmaceutical-grade products (dried flowers, extracts, dronabinol, and CBD), and distributes them to pharmacies across eight European markets under a revenue-sharing model with cultivators. The company complements its product business with patient-facing telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that enable online cannabis prescriptions from experienced cannabis physicians.

Product overview

Cantourage is a European medical cannabis platform that operates a portfolio of products and services. Their core offering includes the Fast Track Access Platform enabling international cultivators to access European markets, combined with pharmaceutical-grade products across all market segments: dried cannabis flowers (imported from 60+ cultivators across 18 countries), cannabis extracts, Dronabinol (pure THC), and CBD products. The company complements its product business with telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that facilitate patient access to cannabis prescriptions. Distribution reaches pharmacies in Germany, the UK, Austria, Switzerland, Poland, Czech Republic, and Denmark.

Differentiator

Problem solved

Functional benefit

Brands

  • Telecan: Telemedicine platform for cannabis prescriptions in Germany, enabling patients to consult with doctors and receive prescriptions online
  • Cantourage Clinic
  • Fast Track Access
  • Hexacan

Quantifiable outcome

  • Revenue of EUR 92.8 million in 2025, up from EUR 51.4 million in 2024 (118% year-over-year growth)
  • +3 more outcomes

Companies that use Cantourage

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Cantourage technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cantourage partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • PharmaVitaecoreChannel Partner/ Reseller/ Distributor · 4 November 2024Polish pharmaceutical distributor partnership for Cantourage's cannabis products. PharmaVitae distributes Cantourage's Gelato 33 and MAC 1 strains to pharmacies across Poland. The partnership targets at least doubling sales from around 500 kg in 2025 to over 1 tonne of cannabis flowers in 2026. PharmaVitae is a Polish private company founded in 2011, specializing in import and distribution of Rx and OTC medicines, medical devices, and cosmetics. It generated PLN 80 million in revenue in 2023.
  • LOT420minorChannel Partner/ Reseller/ Distributor · 4 November 2024Canadian cannabis cultivator supplying the Gelato 33 strain to Cantourage for distribution in Poland through the PharmaVitae partnership. LOT420 is a Canadian producer committed to providing patients with the best possible quality cannabis products.
  • PortocannacoreStrategic or Co-development Partner · 23 May 2024Exclusive strategic partnership with Portuguese medical cannabis processor Portocanna. Portocanna's state-of-the-art EU-GMP certified production facility serves as an additional processing site for Cantourage's cannabis flowers from 65+ cultivation partners in 18 countries, increasing Cantourage's processing capacity by up to six tons per year. The first two products (Supreme Diesel and Fiji Sunset from Green Karat) processed at Portocanna are available in German pharmacies. Additionally, Cantourage gained exclusive distribution rights for Portocanna's 'Hexacan' product line.
  • Green KaratminorChannel Partner/ Reseller/ DistributorCultivation partner supplying cannabis strains (Supreme Diesel and Fiji Sunset) to Cantourage. Products processed at Portocanna and distributed in German pharmacies.
  • Cantourage UKcoreChannel Partner/ Reseller/ DistributorUK subsidiary of Cantourage that distributes products to pharmacies in the United Kingdom and operates the Cantourage Clinic telehealth platform for UK patients.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Cantourage competitors and assessment

Company assessment

Broad incumbents

  • Canopy Growth: Canadian-listed multinational cannabis company with EU medical cannabis distribution. Comparable at the cross-border medical cannabis wholesale layer, though significantly larger and broader than Cantourage's platform.
  • STADA Arzneimittel: German-headquartered European pharmaceutical generics and specialty company with a growing cannabis portfolio (e.g., through partnerships). Comparable as a regulated pharma distribution channel that competes for medical cannabis shelf space in German pharmacies.
  • Aurora Cannabis: Canadian-listed global cannabis producer with European medical cannabis operations. Comparable as a multi-country medical cannabis wholesale supplier but with an integrated cultivation footprint that Cantourage deliberately avoids.
  • Tilray Brands: Large global cannabis incumbent with established EU medical cannabis operations. Comparable to Cantourage at the wholesale/pharmacy-distribution layer but operates a much broader product and geographic portfolio at scale.

Direct peers

  • Avextra: Frankfurt-based medical cannabis operator focused on EU-GMP-certified cultivation and pharmacy distribution across Germany and other European markets. Comparable as a regulated EU medical cannabis producer/distributor competing for the same pharmacy channel.
  • Sanity Group: Berlin-based medical cannabis company operating in Germany across cultivation, processing, and distribution. Directly comparable to Cantourage as a fellow German-headquartered medical cannabis platform with vertically integrated pharmacy and patient access.
  • Cannamedical Pharma: German medical cannabis importer and wholesaler supplying pharmacies across Germany. Directly comparable to Cantourage's wholesale pharmacy distribution model, including its multi-supplier flower portfolio strategy.
  • Demecan: German medical cannabis producer and distributor serving German pharmacies. Directly comparable as a domestic competitor in EU-GMP-certified flower and extract supply to the same pharmacy channels Cantourage targets.
  • Four 20 Pharma: German medical cannabis producer and distributor selling pharmaceutical-grade cannabis to pharmacies. Comparable as a domestic competitor in flower and extract supply to the same regulated German pharmacy channel.
  • CannaCare Health: German medical cannabis distributor and telemedicine operator. Closely comparable to Cantourage because it combines pharmacy-channel distribution with its own doctor/patient access platform — the same hybrid model Cantourage runs via Telecan.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cantourage social profiles

Digital presence

Cantourage compliance and trust

Trust signal

Compliance1 record

Cantourage financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cantourage leadership team

Management profile

Number of profiles

Profiles6 records

Cantourage subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cantourage funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cantourage M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cantourage

What does Cantourage do?

Cantourage imports cannabis raw materials from over 60 cultivation partners across 18 countries, processes them at EU-GMP certified facilities in Germany and Portugal into pharmaceutical-grade products (dried flowers, extracts, dronabinol, and CBD), and distributes them to pharmacies across eight European markets under a revenue-sharing model with cultivators. The company complements its product business with patient-facing telemedicine platforms (Telecan in Germany and Cantourage Clinic in the UK) that enable online cannabis prescriptions from experienced cannabis physicians.

Is Cantourage a public or private company?

Cantourage is a public company. It is classified as public and is currently operating.

When was Cantourage founded?

Cantourage was founded in 2019. It employs 11 to 50 people.

Where is Cantourage based?

Cantourage is headquartered in Berlin, Germany, in the Europe region.

How does Cantourage make money?

Three revenue lines are on record. Cannabis flower processing and distribution is the primary driver. The others are extracts, Dronabinol and CBD and exclusive distribution partnerships.

Who are Cantourage's main competitors?

Broad incumbents on record are Canopy Growth, STADA Arzneimittel, Aurora Cannabis and Tilray Brands. Direct peers are Avextra, Sanity Group, Cannamedical Pharma, Demecan, Four 20 Pharma and CannaCare Health.

Does Cantourage have an API?

No public API is recorded for Cantourage.

What industry is Cantourage in?

Cantourage's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSOriginal-Research: Cantourage Group SE (von First Berlin Equity Research GmbH...Analyst Ellis Acklin reiterated a BUY on Cantourage Group SE, cutting the price target from EUR11 to EUR10.50. Q3 revenue fell 2% year-over-year to EUR19.9m, while gross margin held at 35.3% and EBITDA turned positive at EUR1.9m. The rating remains Buy with 114% upside.Business & FinancialCantourage Group SE Strengthens Profitability And European Market Position Despite Increasing Pricing PressureCantourage Group SE reported Q3 2026 revenue of EUR 19.9 million and EBITDA of EUR 1.9 million, up from a prior-year loss of EUR 2.2 million. Gross margin rose to 35.3% from 18.1%, while Germany's share of revenue fell to 48% as the UK and Poland each contributed about 47% and 6%.FinanzNachrichten.deEQS-News: Cantourage Group SE stärkt Profitabilität und europäische Marktposition trotz zunehmenden PreisdrucksCantourage Group reported Q3 2026 revenue of 19.9M EUR and EBITDA of 1.9M EUR, up from -2.2M EUR a year earlier. Gross margin rose to 35.3% from 18.1%, and foreign markets now contribute over half of revenue, easing German price pressure.Business & FinancialCantourage Further Develops Telecan And Strengthens Digital Access To Medical CareCantourage Group SE is developing Telecan, its telemedicine platform, to add a digital questionnaire-based route for physicians to review treatment requests. The platform will offer this additional access route to complement its existing video consultation service, aiming to strengthen its position in the German medical cannabis market.FinanzNachrichten.deEQS-Adhoc: Cantourage Group SE: Aufsichtsrat beschließt Umstellung auf IFRS im Zuge der erstmaligen Verpflichtung zur KonzernrechnungslegungCantourage Group SE's supervisory board decided to switch to IFRS for its first consolidated financial statements in 2026. The transition shows positive effects on profitability and equity, mainly from goodwill and compensation treatment. A pro-forma comparison will be published in November 2026.TradingViewCantourage Group SE (HIGH) To Transition to IFRS; Preliminary Reconciliation Boosts Earnings and EquityCantourage Group SE will switch consolidated reporting from HGB to IFRS for 2026. A preliminary 2025 reconciliation shows higher earnings and equity, driven by goodwill and share-based compensation treatment. An audited pro forma is expected in early November 2026.Third NewsCantourage and Green Karat Enhance Partnership After EU-GMP CertificationGreen Karat acquired EU-GMP certification on October 1, 2026, strengthening its partnership with Cantourage Group SE. The certification enables Cantourage to import certified cannabis products, enhancing supply chain resilience and expanding manufacturing capacity. Cantourage aims to grow its product portfolio and serve as a conduit for other international producers.FinanzNachrichten.deEQS-News: Cantourage Group SE: Cantourage und Green Karat vertiefen strategische Partnerschaft durch EU-GMP-ZertifizierungGreen Karat received EU-GMP certification on October 1, 2026, and Cantourage became its exclusive distributor in the EU and UK. The certification enables direct imports from Canada, strengthening Cantourage's supply chain and production capacity. Cantourage expects to complete certifications with other producers by end of 2026.TradingViewCantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded MedicinesCantourage Group is expanding its product portfolio with crude extract and distillate from Blue Dream genetics, enabling pharmacies to prepare compounded medicines like solutions, suppositories, vapes, and edibles. The company expects a significant self-pay market segment, less dependent on German statutory health insurance reimbursement. The launch will be presented at expopharm in Munich.FinanzNachrichten.deOriginal-Research: Cantourage Group SE (von Montega AG): KaufenCantourage Group's board issued its first FY26 guidance, projecting revenue of 85-95 million euros and EBITDA of 10-12 million euros. The analyst keeps the Buy rating and 10-euro target, citing margin improvement offsetting German market cleanup.